DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/brrhxs/forest_labs) has announced the addition of the "Forest Labs Clinical Development Profile" report to their offering.
This report provides a thorough analysis of Forest Laboratories' R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest's key products.
In Forest's January 2014 financial conference call they noted that Research and Development spending for the current quarter was approximately $220 million as compared to $325 million reported in the third quarter last year, a reported decrease of 33%,' explained Andrew Schafer, President of ISR.
We certainly did not see Forest's recent acquisition of Aptalis coming or the more recent offer by Actavis to buy Forest Labs for $25 Billion. However, we did realize that Forest was a company in play, Schafer continued.
The report provides pharmaceutical companies and service providers with a look into Forest's individual drug sales and company financial condition over the past four years, the number, length, and patient enrollment of clinical trials segmented by phase and trial type, and Forest's R&D pipeline with mechanism of action identified. This data will help service providers better understand Forest's clinical pipeline while giving sponsors an idea of how these competing compounds may affect the launch of similar products.
Key Topics Covered:
1. Copyright and Usage Guidelines
2. Background and strategy
3. Financial condition
4. R&D pipeline overview
5. Clinical trial activity
7. FDA submissions
8. Key product profiles
For more information visit http://www.researchandmarkets.com/research/brrhxs/forest_labs